Microbiologic activity of the newer macrolide antibiotics

Pediatric Infectious Disease Journal

Volumn 16, Issue 4, 1997, Pages 432-437

  Mccracken Jr , George H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

azithromycin; clarithromycin; erythromycin; penicillin resistance; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFALORAM; CEFIXIME; CEFOTAXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; IMIPENEM; MACROLIDE; PENICILLIN G; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CHILD; CONFERENCE PAPER; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; EAR, MIDDLE; ERYTHROMYCIN; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0343416373     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199704000-00026     Document Type: Conference Paper

References (21)

1. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U. S. medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994;38:2419-25.
2. Brown SD, Burton P, Rich T, Bouchillon SK, Yee YC. Susceptibility surveillance of U. S. respiratory pathogen isolates to newer macrolide and azilide antibiotics. Presented at the 94th General Meeting of the American Society for Microbiology, Las Vegas, NV, 1994.
3. Pass RJ. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother 1993;37: 2080-6.
4. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988;32:1710-9.
5. Felmingham D, Robbins MJ, Sanghrajka M, Leakey A, Ridgway GL. The in vitro activity of some 14-, 15-and 16-membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum. Drugs Exp Clin Res 1991;17:91-9.
6. Welsh L, Gaydos C, Quinn TC. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Antimicrob Agents Chemother 1996;40:212-4.
7. Perlman PE, Ginn DR. Respiratory infections in ambulatory adults. Postgrad Med 1990;87:175-84.
8. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618-24.
9. Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ, Pneumococcal Surveillance Working Group. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis 1991;163:1273-8.
10. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-80.
11. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-5.
12. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40: 1208-13.
13. Mason EO Jr, Kaplan SL, Lamberth LB, Tillman J. Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use. Antimicrob Agents Chemother 1992;36:1703-7.
14. Block SL, Harrison CJ, Hedrick JA, et al. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J 1995;14:751-9.
15. McLinn S, Williams D. Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media. Pediatr Infect Dis J 1996;15:S3-9.
16. Nelson CT, Mason EO Jr, Kaplan SL. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J 1994;13:585-9.
17. Gould IM. Risk factors for acquisition of multiply drug-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1994;13(Suppl 1):30-8.
18. Anderson R, Joone G, van Rensburg CEJ. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988;22:923-33.
19. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
20. Pukander J, Rautianen M. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. J Antimicrob Chemother 1996;37(Suppl C):56-61.
21. Carr RA, Gustavson LE, Palmer RN, et al. Penetration of clarithromycin into middle ear fluid after multiple doses of clarithromycin suspension to pediatric patients with acute otitis media [Abstract 4.04]. Poster presentation at the Third International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, Portugal, January 24 to 26, 1996.